JP2014531401A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531401A5
JP2014531401A5 JP2014522985A JP2014522985A JP2014531401A5 JP 2014531401 A5 JP2014531401 A5 JP 2014531401A5 JP 2014522985 A JP2014522985 A JP 2014522985A JP 2014522985 A JP2014522985 A JP 2014522985A JP 2014531401 A5 JP2014531401 A5 JP 2014531401A5
Authority
JP
Japan
Prior art keywords
compound
therapeutically active
months
active agent
phentolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014522985A
Other languages
English (en)
Other versions
JP6271423B2 (ja
JP2014531401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048263 external-priority patent/WO2013016494A1/en
Publication of JP2014531401A publication Critical patent/JP2014531401A/ja
Publication of JP2014531401A5 publication Critical patent/JP2014531401A5/ja
Application granted granted Critical
Publication of JP6271423B2 publication Critical patent/JP6271423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

安定化組成物において、いかなる治療活性薬剤をも使用し得る。いくつかの実施形態において、治療活性薬剤は、眼科的に許容される液体中で、十分な時間、たとえば少なくとも約３月間、少なくとも約６月間、または少なくとも約１年間、保存できない程度に不安定である。治療活性薬剤のいくつかの非限定的な例には：フェントラミン、化合物１、化合物２、ＤＨＡ、ＥＰＡ、ＡＬＡ、シクロスポリン、ケトロラク、テストステロンまたはそれらの誘導体、もしくはそれらの薬剤的に許容される塩が含まれ得る。
化合物１ 化合物２
JP2014522985A 2011-07-26 2012-07-26 眼送達のための２部製剤 Active JP6271423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161511753P 2011-07-26 2011-07-26
US61/511,753 2011-07-26
PCT/US2012/048263 WO2013016494A1 (en) 2011-07-26 2012-07-26 Two part formulation system for ophthalmic delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017250920A Division JP2018062521A (ja) 2011-07-26 2017-12-27 眼送達のための２部製剤

Publications (3)

Publication Number Publication Date
JP2014531401A JP2014531401A (ja) 2014-11-27
JP2014531401A5 true JP2014531401A5 (ja) 2016-12-28
JP6271423B2 JP6271423B2 (ja) 2018-01-31

Family

ID=46889414

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014522985A Active JP6271423B2 (ja) 2011-07-26 2012-07-26 眼送達のための２部製剤
JP2017250920A Pending JP2018062521A (ja) 2011-07-26 2017-12-27 眼送達のための２部製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017250920A Pending JP2018062521A (ja) 2011-07-26 2017-12-27 眼送達のための２部製剤

Country Status (8)

Country Link
US (4) US20130029919A1 (ja)
EP (2) EP2736475A1 (ja)
JP (2) JP6271423B2 (ja)
KR (1) KR102031997B1 (ja)
CN (2) CN103732202A (ja)
AU (4) AU2012286857B2 (ja)
CA (1) CA2843267C (ja)
WO (1) WO2013016494A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089560B2 (en) 2013-02-01 2015-07-28 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
KR101587412B1 (ko) 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
KR101740869B1 (ko) 2016-12-16 2017-05-29 국제약품 주식회사 설파살라진 및 히알루론산을 함유하는 안약 조성물
CN108707212B (zh) * 2018-05-02 2020-01-07 上海交通大学 一种水溶性共轭聚合物纳米粒子的可控制备方法
JP2022505950A (ja) 2018-10-26 2022-01-14 オキュフィア・ファーマ・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
JPS6452722A (en) * 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US4879304A (en) 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CN1185953A (zh) * 1996-12-27 1998-07-01 刘伟中 富氧舒眼液及其生产工艺
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
SI1073413T1 (ja) 1998-04-29 2005-08-31 Novartis Ag
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
AU7581000A (en) * 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6902335B2 (en) * 2003-05-08 2005-06-07 R.P. Scherer Technologies, Inc. Hand held dispensing and application apparatus
US20060257388A1 (en) * 2005-05-13 2006-11-16 Julius Knowles Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080095754A1 (en) 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
CN101528217A (zh) * 2006-10-18 2009-09-09 博士伦公司 包含二甘氨酸的眼用组合物
DE102007021862A1 (de) * 2007-05-10 2008-11-13 Merck Patent Gmbh Wässrige pharmazeutische Zubereitung
JP5276591B2 (ja) 2007-08-09 2013-08-28 千寿製薬株式会社 ピレノキシン含有二液性点眼剤
GB0718816D0 (en) 2007-09-26 2007-11-07 Intray Ltd Time indicator device
WO2009046967A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
CA2710843A1 (en) * 2008-01-04 2009-07-16 Alcon Pharmaceuticals Ltd. Stable aqueous cyclosporin compositions
US20090221984A1 (en) * 2008-03-03 2009-09-03 Akram Girgis Method and apparatus for providing therapeutically effective dosage formulations of lidocaine with and without epinephrine
SI2915529T1 (sl) * 2008-05-07 2017-09-29 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
CN102028697B (zh) * 2009-09-27 2014-01-08 上海信谊药厂有限公司 含非离子表面活性剂的拉坦前列素滴眼液及制备方法
US20110178147A1 (en) * 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof

Similar Documents

Publication Publication Date Title
JP2014531401A5 (ja)
JP2014507446A5 (ja)
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
JP2010265321A5 (ja)
JP2013014622A5 (ja)
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
JP2011105738A5 (ja)
MX2016006919A (es) Nucleotidos para el tratamiento de cancer de higado.
JP2015078230A5 (ja)
JP2012107057A5 (ja)
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2010005824A (es) Derivados de aminotiazol.
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
JP2011527299A5 (ja)
JP2014218522A5 (ja)
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
AR082875A1 (es) (s)-(4-fluorofenil)(4-((5-metil-1h-pirazol-3-il)amino)quinazolin-2-il)metanol opticamente activo, composiciones farmaceuticas que lo contienen, metodo para prepararlo y uso del mismo como agentes anticancer o antiinflamatorio
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
JP2016532632A5 (ja)